What is the appropriate daily dose of prednisolone oral suspension (15 mg per 5 ml) for an 11.96‑kg child who has been on therapy for 22 months?

Prednisolone Dosing for 22-Month-Old Child (11.96 kg)

For a 22-month-old child weighing 11.96 kg requiring prednisolone therapy, the appropriate daily dose depends critically on the underlying condition being treated, but for most pediatric indications the standard dosing is 1-2 mg/kg/day (approximately 12-24 mg/day for this child), which translates to 4-8 mL of the 15 mg/5 mL suspension.

Clinical Context Assessment

The 15 mg/5 mL concentration (3 mg/mL) is a standard pediatric formulation. However, without knowing the specific diagnosis, I must provide guidance across the most common pediatric conditions requiring prolonged prednisolone therapy:

For Nephrotic Syndrome (Most Likely Given Age and Duration)

Initial/Acute Treatment:

• Daily dose during active disease: 60 mg/m² or 2 mg/kg/day (maximum 60 mg/day) 1, 2
• For this 11.96 kg child: ~24 mg/day = 8 mL of suspension
• Body surface area dosing is preferred but weight-based dosing of 2 mg/kg approximates this in young children 3

Maintenance/Alternate-Day Therapy:

• After achieving remission: 40 mg/m² or 1.5 mg/kg on alternate days (maximum 40 mg) 1
• For this child: ~18 mg every other day = 6 mL on alternate days

Critical Consideration: After 22 months of therapy, this child likely has frequently relapsing or steroid-dependent nephrotic syndrome. The lowest dose to maintain remission without major adverse effects should be used 1. Given the prolonged duration, strongly consider corticosteroid-sparing agents (levamisole, cyclophosphamide, or calcineurin inhibitors) as recommended for children developing steroid-related adverse effects 1.

Dosing Calculation Specifics

Weight-based calculation for this 11.96 kg child:

• 1 mg/kg/day = 11.96 mg ≈ 12 mg = 4 mL
• 1.5 mg/kg/day = 17.94 mg ≈ 18 mg = 6 mL
• 2 mg/kg/day = 23.92 mg ≈ 24 mg = 8 mL

Important caveat: Weight-based dosing (2 mg/kg) systematically underdoses children <30 kg compared to BSA-based dosing (60 mg/m²), with a median ratio of 0.85 3. A practical equation to approximate BSA-based dosing using only weight is: [2 × weight + 8] for 60 mg/m² dosing 4. For this 11.96 kg child: (2 × 12) + 8 = 32 mg/day = 10.7 mL would more accurately match BSA-based dosing.

For Other Conditions

Asthma exacerbation (if applicable):

• 1-2 mg/kg/day in single or divided doses 5
• For this child: 12-24 mg/day = 4-8 mL
• However, asthma typically requires only 3-10 days of therapy, not 22 months 5

Autoimmune conditions:

• Initial: 0.5-1 mg/kg/day 6, 7
• For this child: 6-12 mg/day = 2-4 mL initially

Critical Safety Considerations After 22 Months of Therapy

This prolonged duration raises serious concerns:

1. Growth suppression - Monitor height velocity closely
2. Bone health - Consider bone density assessment and calcium/vitamin D supplementation
3. Adrenal suppression - HPA axis likely suppressed; never stop abruptly 5
4. Infection risk - Ensure vaccinations current (avoid live vaccines if dose >1 mg/kg daily or >2 mg/kg alternate days) 1
5. Ophthalmologic monitoring - Screen for cataracts and glaucoma 6
6. Metabolic effects - Monitor blood pressure, glucose, weight gain

Practical Dosing Algorithm

Step 1: Confirm diagnosis and current disease activity Step 2: If in remission/controlled:

• Use lowest effective dose (often 0.5-1 mg/kg = 6-12 mg = 2-4 mL daily, or alternate-day dosing)
• Consider transition to alternate-day therapy if not already implemented

Step 3: If active disease:

• Use 1.5-2 mg/kg/day = 18-24 mg = 6-8 mL for nephrotic syndrome
• Use 1-2 mg/kg/day = 12-24 mg = 4-8 mL for other conditions

Step 4: After 22 months, urgently evaluate for steroid-sparing agents to minimize cumulative steroid exposure and long-term complications 1

The FDA label confirms pediatric dosing ranges from 0.14-2 mg/kg/day (4-60 mg/m²/day) depending on condition 5, but prolonged therapy at higher doses carries substantial morbidity risk that must be weighed against disease control.